The OPTIN Contact Bulletin

 

New Projects in

IMMUNOLOGY, VACCINE DESIGN, IMMUNOTHERAPY

  AND AUTOIMMUNE DISEASES

from Israel

No 08 - November 2002

www.optin.nl

 

Projects:

1.        Anti cancer vaccine using monoclonal antibody

2.        A novel tool for diagnosis of unbalanced immune response in cancer, immune and infectious diseases

3.        Synthetic genes and their products for potential immune-specific therapy of autoimmune diseases

4.        Developing vaccines and gene targeting vehicles

5.        Clinical studies in cancer immunotherapy

6.        Novel chimeric pharmaceuticals based on human monoclonal antibodies

7.        Cell therapy for autoimmune disease and transplantation

8.        Autoimmune diseases

9.        A novel a subunit vaccine composed of liposome-encapsulated

10.     Gene expression of immunoregulatory proteins as indicator of immune response

11.     Mucosal immunization for viral infections

12.     Neuro-immune interactions

13.     Micro-array technology for monitoring a global state of an immune system

14.     Development of recombinant edible vaccines for veterinary purposes

15.     Therapy for autoimmune diseases

16.     Recombinant fragments of the human acetylcholine receptor

17.     Vaccines for oral immunization against infecting agents

18.     Superantigen toxin antagonist and vaccine

19.     Systemic lupus erythematosus:? a new diagnostic testing system

20.     Computational models of lymphocyte antigen receptor

21.     Use of cop 1 for the prevention of graft rejection

22.     Inactivated influenza vaccine: a novel approach ?

23.     Regulation of granulocyte macrophage-colony stimulating factor (gm-csf) activity

24.     Effects of the immunomodulator as101 on the production of cytokines in vitro and in vivo

25.     Prevention and treatment of EAE (a mouse model for multiple sclerosis) with bacterial and viral proteins

26.     Hsp70 peptides and their uses in the diagnosis and treatment of autoimmune diseases

27.     Recombinant vaccine against IBDV in poultry

28.     Rheumatoid arthritis:? developing a new therapeutic approach

29.     Therapeutic approach to rheumatoid arthritis

30.     Computational biology

31.     Regulation of pancreatic beta-cell proliferation by manipulation of expression of the p57kip2gene

32.     Regeneration of beta-cells

33.     Systemic lupus erythematosus:? a new diagnostic testing system

34.     Systemic lupus erythematosus: a new therapeutic modality

35.     Highly selective monoclonal antibodies for therapeutic, diagnostic, and research purposes

 

 

In the News:

1.     Rhein Biotech and Yissum collaborate in the development of a new Hepetitis B vaccine

2.     Local start-up claims development of revolutionary new cancer treatment

3.     Israeli scientists herald breakthrough in Schizophrenia study

4.     The Jewish mind versus Chemical Attack

 

 

For more information about Life Sciences in Israel and in The Netherlands see the OPTIN site: www.optin.nl your portal to Israeli and Dutch biotechnology.

For background and contact information on the listed projects? please mail to: optin@optin.nl? or call:? +31-(0)70-3643260.

 

Sponsors:

DSM Venturing

IBM Life Sciences

Tel Aviv University

The Embassy of Israel

CIDI

Matimop

Nmedica

 

Contributors:

Tel Aviv University/ Ramot

The Hebrew University/ Yissum

Weizmann Institute/ Yeda

Bar Ilan University

Ben-Gurion University

Hadasit

Technion

Matimop

 

Events:

MEDICA 2002

20-23 November 2002, Germany

BIO-TECH ISRAEL 2003

11-13 March 2003, Tel Aviv,? Israel

AGRITECH 2003 EXHIBITION

19-22 May 2003, Tel Aviv,? Israel

 

Announcement:

Tel Aviv university has published the EOI's for the Sixth Framework on the web, and invites interested partners from the Netherlands (academy and industry) to join the consortia being formed. Contact can be made directly with the coordinator of each group or with the EU liason Office at the address on the web site:

EOI's for the Sixth Framework

Coming up in the next bulletin:

New projects in Information Based Medicine

 

 

For extra information and benefits specifically for sponsors, please contact OPTIN.